Revolution Medicines Inc

For the period ended Dec 31, 2023. Filed Feb 26, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 26, 2024

RVMD$193.06-3.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Stockholders’ Equity

Accumulated
Additional · Other · Total
Common Stock · Paid-in · Comprehensive · Accumulated · Stockholders'
Shares · Amount · Capital · Income/ (Loss) · Deficit · Equity
Balance at December 31, 2020	66,599,748	$7	$740,098	$116	$(265,545)		$474,676
Issuance of common stock pursuant to stock option exercises	388,695	—	1,487	—	—		1,487
Issuance of common stock related to employee stock purchase plan	75,991	—	1,875	—	—		1,875
Issuance of common stock related to vesting of restricted stock units	78,010	—	—	—	—		—
Vesting of early exercised stock options	—	—	148	—	—		148
Repurchases of early exercised stock	(5,793)	—	—	—	—		—
Issuance of common stock from follow-on public offering, net of offering costs of $18,855	6,666,666	1	281,144	—	—		281,145
Issuance of common stock from at-the-market offering	339,302	—	10,096	—	—		10,096
Stock-based compensation expense	—	—	20,724	—	—		20,724
Net unrealized loss on marketable securities	—	—	—	(492)	—		(492)
Net loss	—	—	—	—	(187,091)		(187,091)
Balance at December 31, 2021	74,142,619	$8	$1,055,572	$(376)	$(452,636)		$602,568
Issuance of common stock pursuant to stock option exercises	249,544	—	1,481	—	—		1,481
Issuance of common stock from follow-on public offering, net of offering costs of $16,374	13,225,000	1	248,125	—	—		248,126
Issuance of common stock related to vesting of restricted stock units	278,848	—	—	—	—		—
Issuance of common stock related to employee stock purchase plan	130,327	—	1,864	—	—		1,864
Issuance of common stock from at-the-market offering	2,385,846	—	49,919	—	—		49,919
Repurchases of early exercised stock	(272)	—	—	—	—		—
Vesting of early exercised stock options	—	—	143	—	—		143
Stock-based compensation expense	—	—	31,196	—		31,196
Net unrealized loss on marketable securities	—	—	—	(1,404)	—		(1,404)
Net loss	—	—	—	—	(248,705)		(248,705)
Balance at December 31, 2022	90,411,912	$9	$1,388,300	$(1,780)	$(701,341)		$685,188
Issuance of common stock pursuant to stock option exercises	524,094	—	3,316	—	—		3,316
Issuance of common stock from follow-on public offering, net of offering costs of $21,294	15,681,818	2	323,704	—	—		323,706
Issuance of common stock in connection with acquisition of EQRx, Inc., net of transaction costs of $20,717	54,786,528	5	1,120,880	—	—		1,120,885
Issuance of common stock from at-the-market offering	2,482,880	—	62,053	—	—		62,053
Issuance of common stock related to vesting of restricted stock units	576,974	—	—	—	—		—
Issuance of common stock related to employee stock purchase plan	210,679	—	3,317	—	—		3,317
Repurchases of early exercised stock	(291)	—	—	—	—		—
Stock-based compensation expense	—	—	61,772	—	—		61,772
Net unrealized gain on marketable securities	—	—	—	2,324	—		2,324
Net loss	—	—	—	—	(436,367)		(436,367)
Balance at December 31, 2023	164,674,594	$16	$2,963,342	$544	$(1,137,708)		$1,826,194

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.